Gena H. Volas-Redd
Expertise in
58
conditions

Dr. Gena H. Volas-Redd

Hematology | Oncology
790 Church Street Northeast, Suite 335, 
Marietta, GA 
Expertise in
58
conditions
790 Church Street Northeast, Suite 335, 
Marietta, GA 

Overview

Gena Volas-Redd is a Hematologist and an Oncologist practicing medicine in Marietta, Georgia.

Dr. Volas-Redd is highly rated in 58 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Astrocytoma, and Metastatic Brain Tumor.

Dr. Volas-Redd is board certified in American Board Of Internal Medicine - Medical Oncology. She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine - Medical Oncology

Fellowships

Emory University School of Medicine, Hematology/Oncology, 2000
University of Pennsylvania School of Medicine, Hematology/Oncology, 1998

Hospital Affiliations

Wellstar Paulding Medical Center
Northside Hospital Forsyth
Northside Hospital Cherokee
Wellstar Kennestone Regional Medical Center
Northside Hospital

Languages Spoken

English
Greek
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Georgia Cancer Specialists
790 Church Street Northeast, Suite 335, Marietta, GA 30060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Enrollment Status: Completed
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drug: Ramipril
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Metformin, Dapagliflozin
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

2 Total Publications

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Journal: Clinical breast cancer
Published: November 14, 2018
Similar Doctors
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (15.1 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Referral may be required

Egleston Children's Hospital At Emory

1405 Clifton Rd NE, 
Atlanta, GA 
 (15.7 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lakshmanan Krishnamurti is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Referral may be required

Office

1760 Haygood Dr NE, 
Atlanta, GA 
 (15.8 miles away)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tobey Macdonald is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Macdonald is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor. Dr. Macdonald is currently accepting new patients.

Frequently Asked Questions about Dr. Gena H. Volas-Redd

How do I make an appointment with Dr. Gena H. Volas-Redd?

You can book an appointment with Dr. Gena H. Volas-Redd by calling their office at 770-590-8311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gena H. Volas-Redd a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gena H. Volas-Redd is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gena H. Volas-Redd specialize in?

While Dr. Gena H. Volas-Redd is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Gena H. Volas-Redd participate in research or clinical trials?

Yes. Dr. Gena H. Volas-Redd has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Gena H. Volas-Redd's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gena H. Volas-Redd accept my insurance?

Dr. Gena H. Volas-Redd accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 770-590-8311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Volas-Redd's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 40 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile